Researchers reported that there was still a disparity between objective and patient-based measures of chronic rhinosinusitis in individuals with cystic fibrosis (CF) who were treated with highly effective modulator therapy, and published their findings in the International Forum of Allergy & Rhinology.

One of the keys to boosting the quality of life in patients with CF is to effectively manage sinonasal manifestations associated with CF, the authors said. Fortunately, current therapy, namely the CF transmembrane highly effective modulator therapy and elexacaftor/tezacaftor/invacaftor (ELX/TEZ/IVA), improve pulmonary disease and chronic rhinosinusitis in these patients.

“Correlations between patient-reported outcomes and objective measures of sinonasal disease severity have not been adequately studied in [patients with CF],” the authors said. The research team set out to investigate any possible correlations in improvements in sinonasal disease severity before and after the use of highly effective modulator therapy.

Read more about CF therapies

The research team recruited patients with both chronic rhinosinusitis and CF. They were then subjected to ELX/TEZ/IVA treatment. Various tests were carried out at baseline and after six months of therapy.

The results demonstrated that although highly effective modulator therapy improves chronic rhinosinusitis in patients with CF across patient-reported and objective measures of disease, the research team found no correlation between improvements in sinonasal symptoms and radiological findings, an outcome that surprised the authors of the study.

“However, this result is consistent with previous studies in other populations that primarily demonstrated a lack of correlation between patient-reported and objective measures of [chronic rhinosinusitis] severity,” they wrote. These findings demonstrate the complex relationship in patients with CF with regards to sinonasal symptoms, the general quality of life, and inflammation in the airways.

“In [patients with CF], management of both sinonasal symptoms and objective sinus inflammation is critical to optimize [quality of life] and minimize lower airway effects that stem from upper airway disease,” the authors concluded.

Reference

Beswick DM, Humphries SM, Miller JE, et al. Objective and patient-based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapyInt Forum Allergy Rhinol. Published online May 20, 2022. doi:10.1002/alr.23016